Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.93 CHF | +1.02% | -14.16% | +99.71% |
04-24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
04-17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.7M 26.9M | Sales 2023 | 33.56M 36.77M 50.19M | Capitalization | 128M 141M 192M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.34M -20.94M | Net income 2023 | -13M -14.24M -19.44M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.19M 33.03M | Net cash position 2023 | 12M 13.14M 17.94M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
1 day | +1.02% | ||
1 week | -14.16% | ||
Current month | +15.02% | ||
1 month | +16.36% | ||
3 months | +32.51% | ||
6 months | +168.08% | ||
Current year | +99.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 6.97 | +1.60% | 32 |
24-04-26 | 6.86 | -0.44% | 115,481 |
24-04-25 | 6.89 | +2.38% | 201,239 |
24-04-24 | 6.73 | -5.34% | 430,265 |
24-04-23 | 7.11 | -12.44% | 601,803 |
Delayed Quote Swiss Exchange, April 29, 2024 at 03:01 am
More quotes1st Jan change | Capi. | |
---|---|---|
+99.71% | 276M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.93% | 22.15B | |
-17.37% | 21.02B | |
-9.10% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KURN Stock